Amelioration of the severity of heparin-binding antithrombin mutations by posttranslational mosaicism

Blood

Volumn 120, Issue 4, 2012, Pages 900-904

  Martińez Martínez, Irene ^a   Navarro Fernández, José ^b   Østergaard, Alice ^c   Gutiérrez Gallego, Ricardo ^a   Padilla, José ^a   Bohdan, Nataliya ^a   Miñano, Antonia ^d   Pascual, Cristina ^a   Martínez, Constantino ^a   De La Morena Barrio, Mariá Eugenia ^a   Águila, Sonia ^b   Pedersen, Shona ^b   Kristensen, Søren Risom ^a   Vicente, Vicente ^a   Corral, Javier ^a  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN BINDING PROTEIN;

ARTICLE; BINDING AFFINITY; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; GENE MUTATION; HUMAN; MOSAICISM; PRIORITY JOURNAL; PROTEIN PROCESSING; THROMBOSIS;

EID: 84864493144     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-406207     Document Type: Article

References (27)

1. Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol. 1981;10(2):369-390.
2. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood. 2008;112(1):19-27.
3. Lane DA, Bayston T, Olds RJ, et al. Antithrombin mutation database: 2nd (1997) update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1997;77(1):197-211. (Pubitemid 27064991)
4. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest. 2000;106(7):873-878.
5. Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci U S A. 1984;81(2):289-293. (Pubitemid 14185715)
6. Kristensen SR, Kaehne M, Petersen NE. Hemizygous antithrombin-deficiency (Budapest III) in a newborn presenting with a thrombosis at birth. Br J Haematol. 2007;138(3):397-398. (Pubitemid 47035394)
7. Kuhle S, Lane DA, Jochmanns K, et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost. 2001;86(4):1007-1011. (Pubitemid 32975825)
8. Olson ST, Chuang YJ. Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med. 2002;12(8):331-338. (Pubitemid 36092123)
9. Arocas V, Bock SC, Olson ST, Bjork I. The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry. 1999;38(31):10196-10204.
10. Olds RJ, Lane DA, Boisclair M, et al. Antithrombin Budapest 3. An antithrombin variant with reduced heparin affinity resulting from the substitution L99F. FEBS Lett. 1992;300(3):241-246.
11. Chang JY, Tran TH. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem. 1986;261(3):1174-1176. (Pubitemid 16103923)
12. Corral J, Huntington JA, Gonzalez-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost. 2004(6);2:931-939. (Pubitemid 40185741)
13. Mushunje A, Evans G, Brennan SO, Carrell RW, Zhou A. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost. 2004;2(12):2170-2177. (Pubitemid 40185778)
14. Langdown J, Belzar KJ, Savory WJ, Baglin TP, Huntington JA. The critical role of hinge-region expulsion in the induced-fit heparin binding mechanism of antithrombin. J Mol Biol. 2009;386(5):1278-1289.
15. Martinez-Martinez I, Ordonez A, Navarro-Fernandez J, et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica. 2010;95(8):1358-1365.
16. Perez-Perez JM, Candela H, Micol JL. Understanding synergy in genetic interactions. Trends Genet. 2009;25(8):368-376.
17. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM. Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic. 2004;5(11):821-837. (Pubitemid 39433553)
18. Helderman-van den EndenAT, van den Bergen JC, Breuning MH, et al. Duchenne/Becker muscular dystrophy in the family: have potential carriers been tested at a molecular level? Clin Genet. 2011;79(3):236-242.
19. Gregory JJ Jr, Wagner JE, Verlander PC, et al. Somatic mosaicism in Fanconi anemia: evidence of genotypic reversion in lymphohematopoietic stem cells. Proc Natl Acad Sci U S A. 2001;98(5):2532-2537. (Pubitemid 32209516)
20. Kasper CK, Buzin CH. Mosaics and haemophilia. Haemophilia. 2009;15(6):1181-1186.
21. Stamm S, Ben-Ari S, Rafalska I, et al. Function of alternative splicing. Gene. 2005;344:1-20. (Pubitemid 40126788)
22. Yan Q, Lennarz WJ. Oligosaccharyltransferase: a complex multisubunit enzyme of the endoplasmic reticulum. Biochem Biophys Res Commun. 1999;266(3):684-689. (Pubitemid 30042493)
23. McCoy AJ, Pei XY, Skinner R, Abrahams JP, Carrell RW. Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J Mol Biol. 2003;326(3):823-833. (Pubitemid 36279322)
24. Turk B, Brieditis I, Bock SC, Olson ST, Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36(22):6682-6691. (Pubitemid 27242326)
25. Swedenborg J. The mechanisms of action of alpha- and beta-isoforms of antithrombin. Blood Coagul.Fibrinolysis. 1998;9(Suppl 3):S7-S10.
26. Luxembourg B, Delev D, Geisen C, et al. Molecular basis of antithrombin deficiency. Thromb Haemost. 2011;105(4):635-646.
27. Berry LR, Thong B, Chan AK. Comparison of recombinant and plasma-derived antithrombin biodistribution in a rabbit model. Thromb Haemost. 2009;102(2):302-308.